fluorouracil has been researched along with Mandibular Diseases in 2 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Mandibular Diseases: Diseases involving the MANDIBLE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Longo, M | 1 |
| Gouveia Garcia, V | 1 |
| Ervolino, E | 1 |
| Ferro Alves, ML | 1 |
| Duque, C | 1 |
| Wainwright, M | 1 |
| Theodoro, LH | 1 |
| Salama, JK | 1 |
| Vokes, EE | 1 |
| Chmura, SJ | 1 |
| Milano, MT | 1 |
| Kao, J | 1 |
| Stenson, KM | 1 |
| Witt, ME | 1 |
| Haraf, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS
| Intervention | participants (Number) |
|---|---|
| Celecoxib 200mg | 0 |
| Celecoxib 400mg | 1 |
| Celecoxib 600mg | 2 |
Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response(CR) | Pathologic partial response (pPR) | Progressive disease (PD) | No evidence of disease (NED) | |
| Erlotinib + Celecoxib | 6 | 1 | 5 | 2 |
At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| locoregional control | progress-free survival | overall survival rates | long term toxicity | |
| Erlotinib + Celecoxib | 60 | 37 | 55 | 0 |
Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| free of disease | isolated locoregional progression | isolated distant progression | both locoregional and distant progression | no evidence of disease, died of comorbid illness | |
| Erlotinib + Celecoxib | 4 | 4 | 2 | 1 | 3 |
2 other studies available for fluorouracil and Mandibular Diseases
| Article | Year |
|---|---|
Multiple aPDT sessions on periodontitis in rats treated with chemotherapy: histomorphometrical, immunohistochemical, immunological and microbiological analyses.
Topics: Aggregatibacter actinomycetemcomitans; Alveolar Bone Loss; Animals; Dental Scaling; Disease Models, | 2019 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2006 |